Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opicapone - BIAL

Next Previous
Search
Drug Profile

Opicapone - BIAL

Alternative Names: [14C]-BIA 9-1067; BIA-91067; Ongentys; ONO-2370

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BIAL
  • Developer BIAL; Neurocrine Biosciences; Ono Pharmaceutical
  • Class Antiparkinsonians; Nitrobenzenes; Oxadiazoles; Oxides; Pyridines
  • Mechanism of Action Catechol O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 26 Jan 2024 BIAL completes a phase III EPSILON trial for Parkinson's disease (Adjunctive treatment) in Czech Republic, Bularia, France, Belgium, Italy and Portugal (EudraCT2020-005011-52)
  • 07 Dec 2023 Amneal Pharmaceuticals and BIAL eneters into a licensing agreement to market and distribute opicapone
  • 03 May 2023 Neurocrine Biosciences provides BIAL with written notice of termination of the license agreement to commercialize and market Opicapone in USA and Canada

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top